# US 2021/0172017 A1 · Methods of in vivo evaluation of gene function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172017 A1
- Document ID: US20210172017A1
- Status: Published application
- Kind: A1
- Application number: 17/163,015
- Filed: 2021-01-29
- Published: 2021-06-10
- Earliest claimed: 2019-09-19
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology; President and Fellows of Harvard College
- Applicants: The Broad Institute, Inc.; Massachusetts Institute of Technology; President and Fellows of Harvard College
- Inventors: Xin Jin; Paola Arlotta; Aviv Regev; Feng Zhang; Sean Simmons
- Web page: https://patentgrep.com/patent/US20210172017A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/907: {in mammalian cells}
- C12Q 1/6897: involving reporter genes operably linked to promoters
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/12: in functional genomics, i.e. for the determination of gene function
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12Q 2600/136: Screening for pharmacological compounds
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods and uses thereof for in vivo evaluating functions of multiple genes in parallel by combining in utero genetic perturbation of progenitor cells and single-cell transcriptomic profiling of progeny cells in animals. These methods can be used, among other things, to reveal in vivo gene functions in a cell type-specific manner.

## Claims

### Claim 1

A method of identifying functions of a plurality of genes in parallel in vivo, comprising:
a. introducing, in vivo, a plurality of genetic perturbations in each of a plurality of progenitor cells in a Cas animal model, wherein each genetic perturbation is operatively coupled to a reporter gene and a barcode;
b. generating an enriched perturbed cell population by enriching for cells expressing the reporter;
c. identifying cell types and corresponding perturbations via scRNA-seq in the enriched perturbed cell population; and
d. detecting one or more gene modules that co-vary within a cell type in the enriched perturbed cell population.

### Claim 2 (depends on 1)

The method of claim 1, wherein the enriched perturbed cell population comprises progenitor cell progeny.

### Claim 3 (depends on 1)

The method of claim 1, wherein the plurality of genetic perturbations are introduced using two or more guide RNAs (gRNAs) for each target gene, wherein the two or more gRNAs each bind to s sequence of an exon, an intron, or both at the 5′ end of a target gene.

### Claim 4 (depends on 3)

The method of claim 3, wherein two or more gRNAs each bind to a sequence of a coding exon at the 5′ end of a target gene.

### Claim 5 (depends on 3)

The method of claim 3, wherein each of the two or more gRNAs are controlled by a different pol III promoter.

### Claim 6 (depends on 5)

The method of claim 5, wherein expression of a first gRNA of the two or more gRNAs is driven by a human pol III promoter and wherein expression of a second gRNA of the two or more gRNAs is driven by a non-human pol III promoter.

### Claim 7 (depends on 6)

The method of claim 6, wherein the human pol III promoter and the non-human pol III promoters are each independently selected from a U6, a 7SK, or an H1 promoter.

### Claim 8 (depends on 5)

The method of claim 5, wherein one or more of the pol III promoters are constitutive.

### Claim 9 (depends on 5)

The method of claim 5, wherein one or more of the pol III promoters are inducible.

### Claim 10 (depends on 1)

The method of claim 1, wherein the barcode is polyadenylated.

### Claim 11 (depends on 6)

The method of claim 6, wherein the reporter gene is controlled by a constitutive pol II promoter.

### Claim 12 (depends on 1)

The method of claim 1, wherein introducing further comprises delivering to the plurality of progenitor cells a pool of engineered virus particles comprising equal genetic perturbation representation.

### Claim 13 (depends on 11)

The method of claim 11, wherein the engineered virus particles are engineered lentiviral particles.

### Claim 14 (depends on 11)

The method of claim 11, wherein introducing further comprises delivering the pool of engineered virus particles to a target tissue of a developing embryo of the Cas animal model in utero.

### Claim 15 (depends on 13)

The method of claim 13, wherein the developing embryo is at stage between E5-E15 or an equivalent stage thereof.

### Claim 16 (depends on 10)

The method of claim 10, wherein the reporter gene encodes an optically active protein.

### Claim 17 (depends on 10)

The method of claim 10, wherein the reporter gene encodes a cell surface molecules selected from the group of: CD3, CD4, CD19, CD20, CD22, CD34, CD45, CD80, a cell surface receptor, a cluster differentiation (CD) molecule, or any combination thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the Cas animal model constitutively or inducibly expresses a Cas protein in one of, a plurality of, or all of its cells.

### Claim 19 (depends on 17)

The method of claim 17, wherein the Cas protein is a Cas Type I, II, III, IV, or V protein.

### Claim 20 (depends on 1)

The method of claim 1, wherein identifying further comprises a genomic analysis, an epigenomic analysis, a transcriptomic analysis, a proteomic analysis, or a combination thereof.

### Claim 21 (depends on 1)

The method of claim 1 further comprising a genomic analysis, an epigenomic analysis, a transcriptomic analysis, a proteomic analysis, or a combination thereof.

### Claim 22 (depends on 1)

The method of claim 1, wherein the plurality of genes are autism spectrum disorder associated genes.

### Claim 23 (depends on 1)

A method of in vivo screening for therapeutic targets useful for developing treatment for a disease, comprising:
a. performing a method as in claim 1, wherein the plurality of genes are a plurality of candidate genes; and
b. selecting one or more candidate genes that produce a change in one or more identified gene modules that are indicative of the disease status; whereby the selected one or more candidate genes are identified as therapeutic targets for disease treatment screening.

### Claim 24 (depends on 23)

The method of claim 23, further comprising using the selected candidate gene(s) as therapeutic targets in a disease treatment screen.

### Claim 25 (depends on 24)

The method of claim 24, wherein the disease treatment screen is an autism spectrum disease treatment screen.

### Claim 26 (depends on 23)

The method of claim 23, wherein the disease is an autism spectrum disease.

### Claim 27 (depends on 23)

A therapeutic agent for treating a disease, wherein the therapeutic agent is capable of modifying the function, activity, expression, or a combination thereof of identified therapeutic targets of claim 23, one or more gene product(s) thereof, or both.

### Claim 28 (depends on 27)

The method of claim 27, wherein the disease is an autism spectrum disease.
